Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
BPN14770 is an inhibitor of phosphodiesterase 4D (PDE4D).1 It selectively inhibits dimeric PDE4DS129D and PDE4DS54D, which mimic the phosphorylated, activated forms of PDE4D, over wild-type dimeric PDE4D, dimeric PDE4DS133D, and monomeric PDE4D2 (IC50s = 7.8, 7.4, 1,018, 2,013, and 127 nM, respectively). BPN14770 (0.3-30 mg/kg) enhances novel object discrimination in mice. It decreases hyperarousal and increases social interaction time, indicating anxiolytic-like activity, nesting, and marble-burying behavior in the Fmr1-/- mouse model of fragile X syndrome when administered at a dose of 0.3 mg/kg.2
WARNING This product is not for human or veterinary use.
1. Design and synthesis of selective phosphodiesterase 4D (PDE4D) allosteric inhibitors for the treatment of Fragile X Syndrome and other brain disorders. J. Med. Chem. 62(10), 4884-4901 (2019).
2. Multiple Behavior Phenotypes of the Fragile-